The present study indicated that VK1 could enhance sorafenib-induced growth inhibition and apoptosis of glioma cells, and this synergistic effectiveness was associated with the downregulation of the Raf/MEK/ERK signaling pathway. This evidence concerns the gene MAP2K7 and central nervous system cancer.